Vcanbio Cell & Gene Engineering Corp Ltd (600645) - Total Assets
Based on the latest financial reports, Vcanbio Cell & Gene Engineering Corp Ltd (600645) holds total assets worth CN¥5.27 Billion CNY (≈ $770.45 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Vcanbio Cell & Gene Engineering Corp Ltd debt service capacity to assess how comfortably operating cash covers total debt obligations.
Vcanbio Cell & Gene Engineering Corp Ltd - Total Assets Trend (1992–2025)
This chart illustrates how Vcanbio Cell & Gene Engineering Corp Ltd's total assets have evolved over time, based on quarterly financial data. See 600645 book value for net asset value and shareholders' equity analysis.
Vcanbio Cell & Gene Engineering Corp Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Vcanbio Cell & Gene Engineering Corp Ltd's total assets of CN¥5.27 Billion consist of 50.2% current assets and 49.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 19.0% |
| Accounts Receivable | CN¥605.87 Million | 11.5% |
| Inventory | CN¥230.23 Million | 4.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥156.88 Million | 3.0% |
| Goodwill | CN¥702.91 Million | 13.3% |
Asset Composition Trend (1992–2025)
This chart illustrates how Vcanbio Cell & Gene Engineering Corp Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 600645 market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vcanbio Cell & Gene Engineering Corp Ltd's current assets represent 50.2% of total assets in 2025, a decrease from 62.0% in 1992.
- Cash Position: Cash and equivalents constituted 19.0% of total assets in 2025, up from 8.1% in 1992.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, an increase from 0.0% in 1992.
- Asset Diversification: The largest asset category is goodwill at 13.3% of total assets.
Vcanbio Cell & Gene Engineering Corp Ltd Competitors by Total Assets
Key competitors of Vcanbio Cell & Gene Engineering Corp Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Prostemics Co. Ltd
KQ:203690
|
Korea | ₩39.70 Billion |
|
ORUM
KQ:475830
|
Korea | ₩191.52 Billion |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
TG Therapeutics Inc
NASDAQ:TGTX
|
USA | $1.53 Billion |
|
Green Cross Holdings Preference Shares
KO:005257
|
Korea | ₩4.12 Trillion |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $285.41 Million |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5
|
Germany | €40.03 Million |
|
Cybin Inc
NEO:CYBN
|
Canada | CA$290.11 Million |
Vcanbio Cell & Gene Engineering Corp Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.88 | 1.70 | 1.47 |
| Quick Ratio | 1.72 | 1.53 | 1.31 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.25 Billion | CN¥1.02 Billion | CN¥640.36 Million |
Vcanbio Cell & Gene Engineering Corp Ltd - Advanced Valuation Insights
This section examines the relationship between Vcanbio Cell & Gene Engineering Corp Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.29 |
| Latest Market Cap to Assets Ratio | 0.24 |
| Asset Growth Rate (YoY) | 0.8% |
| Total Assets | CN¥5.29 Billion |
| Market Capitalization | $1.29 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Vcanbio Cell & Gene Engineering Corp Ltd's assets below their book value (0.24x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Vcanbio Cell & Gene Engineering Corp Ltd's assets grew by 0.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Vcanbio Cell & Gene Engineering Corp Ltd (1992–2025)
The table below shows the annual total assets of Vcanbio Cell & Gene Engineering Corp Ltd from 1992 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥5.29 Billion ≈ $774.42 Million |
+0.83% |
| 2024-12-31 | CN¥5.25 Billion ≈ $768.09 Million |
-3.00% |
| 2023-12-31 | CN¥5.41 Billion ≈ $791.85 Million |
+2.40% |
| 2022-12-31 | CN¥5.28 Billion ≈ $773.31 Million |
+4.99% |
| 2021-12-31 | CN¥5.03 Billion ≈ $736.54 Million |
+3.15% |
| 2020-12-31 | CN¥4.88 Billion ≈ $714.03 Million |
-0.18% |
| 2019-12-31 | CN¥4.89 Billion ≈ $715.35 Million |
+10.02% |
| 2018-12-31 | CN¥4.44 Billion ≈ $650.21 Million |
+48.12% |
| 2017-12-31 | CN¥3.00 Billion ≈ $438.99 Million |
-0.12% |
| 2016-12-31 | CN¥3.00 Billion ≈ $439.53 Million |
+6.66% |
| 2015-12-31 | CN¥2.82 Billion ≈ $412.09 Million |
+16.52% |
| 2014-12-31 | CN¥2.42 Billion ≈ $353.67 Million |
+62.76% |
| 2013-12-31 | CN¥1.48 Billion ≈ $217.30 Million |
+20.39% |
| 2012-12-31 | CN¥1.23 Billion ≈ $180.49 Million |
+45.53% |
| 2011-12-31 | CN¥847.56 Million ≈ $124.02 Million |
+9.83% |
| 2010-12-31 | CN¥771.69 Million ≈ $112.92 Million |
+10.25% |
| 2009-12-31 | CN¥699.94 Million ≈ $102.42 Million |
+7.40% |
| 2008-12-31 | CN¥651.74 Million ≈ $95.37 Million |
+10.72% |
| 2007-12-31 | CN¥588.65 Million ≈ $86.14 Million |
+1.60% |
| 2006-12-31 | CN¥579.39 Million ≈ $84.78 Million |
+18.78% |
| 2005-12-31 | CN¥487.80 Million ≈ $71.38 Million |
-12.72% |
| 2004-12-31 | CN¥558.90 Million ≈ $81.78 Million |
-12.13% |
| 2003-12-31 | CN¥636.09 Million ≈ $93.08 Million |
+12.10% |
| 2002-12-31 | CN¥567.42 Million ≈ $83.03 Million |
-27.38% |
| 2001-12-31 | CN¥781.36 Million ≈ $114.34 Million |
+15.19% |
| 2000-12-31 | CN¥678.36 Million ≈ $99.26 Million |
+2.88% |
| 1999-12-31 | CN¥659.36 Million ≈ $96.49 Million |
-2.05% |
| 1998-12-31 | CN¥673.16 Million ≈ $98.50 Million |
+10.99% |
| 1997-12-31 | CN¥606.51 Million ≈ $88.75 Million |
+40.65% |
| 1996-12-31 | CN¥431.22 Million ≈ $63.10 Million |
+8.89% |
| 1995-12-31 | CN¥396.03 Million ≈ $57.95 Million |
+40.93% |
| 1994-12-31 | CN¥281.02 Million ≈ $41.12 Million |
+54.30% |
| 1993-12-31 | CN¥182.13 Million ≈ $26.65 Million |
+52.56% |
| 1992-12-31 | CN¥119.38 Million ≈ $17.47 Million |
-- |
About Vcanbio Cell & Gene Engineering Corp Ltd
Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, engages in the preparation and storage of cell detection tests in the People's Republic of China. It offers cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, immune cells, adipose stem cells, and dental ste… Read more